Ultimately, the management goal is not for patients with relapsed/refractory disease to live with chronic Hodgkin lymphoma while receiving immune checkpoint blockade therapy, but rather to cure more patients with first- or second-line therapy.
Anita Kumar, MD
Advertisement
Articles by Anita Kumar, MD
Advertisement
Latest Updated Articles
- The Emerging Role of Checkpoint Inhibitor Therapy in Hodgkin Lymphoma
Published: October 15th 2016 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
2
How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap
3
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
4
Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL
5
